Tools and Technology for a Better Life
Delray Beach, FL (PRWEB) February 22, 2012
PositiveID Corporation (OTCBB: PSID) a developer of medical technologies for diabetes management, clinical diagnostics and bio-threat detection has made major developments so far in 2012 positioning the group for its greatest success and achievements to date. “Not since the end of the great depression has there been such opportunity in the stock market for the tremendous financial goals to be met by individuals and or groups who are able to recognize and take advantage of situations created by unique scenarios in the economy, technologies, and the market place” states Randy Segal of Mass Media 77. “PositiveID has combined all of these into one special situation” Randy goes on to say. PositiveID is a stock that has been trading under US$0.25 per share and has made these incredible achievements from the end of 2011 and since the beginning of 2012 in just a few months:
•iglucose Paves Way for Non-Invasive, Painless, and Bloodless Glucose Checker
•PositiveID Corporation Announces Initiation of Clinical Trial of Its Easy Check Non- Invasive Breath Glucose Detection Device
•PositiveID Clears Final FCC Hurdle to Sell iglucose(TM) System in US
Now one of the biggest scenarios is opening for PositiveID in the form of their M-BAND system for PositiveID's subsidiary MicroFluidic Systems. The BioWatch program is the nation's first early warning network of sensors to detect biological attacks as announced here in Yahoo Finance. This puts PositiveID in position to participate as one of a small group to potentially share in over a U$3 Billion contract established by the Department of Homeland Security for an early warning and detection system in the US against airborne biological threats. PositiveID has patents that lead the way for this technology and is building the relationships to partner with such groups as the Boeing Company and Hamilton Sundstrand in order to create liasons with companies more accustomed to securing government contracts of this size and importance. These strategic allies also combine the successful patents and research with the resources and capabilities of leaders with long time track records for procuring and delivering contracts and agreements with government agencies worldwide.
The combination of incredible advances in technology that brings managing diabetes to a painless, effortless system and creates the ability for people to live more productive lives while reducing health care expenses for the end users as well as health care providers, along with providing an overall sense of security and wellbeing for all Americans with the bio threat detection system, makes PositiveID a unique, one-of-a-kind opportunity for many. With the stock price at such an attractive level it allows the opportunity to gain a leveraged position that normally doesn’t occur on the average.
PositiveID Corporation (OTCBB: PSID) develops unique medical devices and molecular diagnostic systems like the Ricin Detection systems noted in the Digital Journal release. PositiveID focuses primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MicroFluidic Systems or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays.
For more information please email:
Copyright © 2012 All rights reserved.
PR: http://www.MassMedia77.com Sound Marketing is Smart Business
Safe Harbor Statement
This report includes forward-looking statements covered by the Private Securities Litigation Reform Act of 1995. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results for fiscal year 2010 and beyond could differ materially from the Company’s current expectations.
Forward-looking statements are identified by words such as “anticipates,” “projects,” “expects,” “plans,” “intends,” “believes,” “estimates,” “targets,” and other similar expressions that indicate trends and future events.
Factors that could cause the Company’s results to differ materially from those expressed in forward-looking statements include, without limitation, variation in demand and acceptance of the Company’s products and services, the frequency, magnitude and timing of paper and other raw-material-price changes, general business and economic conditions beyond the Company’s control, timing of the completion and integration of acquisitions, the consequences of competitive factors in the marketplace including the ability to attract and retain customers, results of the MyC3 initiative and other cost-containment strategies, and the Company’s success in attracting and retaining key personnel. Additional information concerning factors that could cause actual results to differ materially from those projected is contained in the Company’s filing with The Securities and Exchange Commission. The Company undertakes no obligation to revise or update forward-looking statements as a result of new information since these statements may no longer be accurate or timely.
Analysts’ Compensation: Mass Media 77, Inc. who in part or in whole may be responsible for the preparation of this report may receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which include revenues from, among other business units, Institutional Equities and Investment Banking and restricted stock.
Information has been obtained from sources believed to be reliable but Mass Media 77, Inc or its affiliates and/or subsidiaries (collectively Mass Media 77, Inc.) do not warrant its completeness or accuracy. Opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Past performance is not indicative of future results. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. The recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein. Periodic updates may be provided on companies/industries based on company specific developments or announcements, market conditions or any other publicly available information. Additional information may be available upon request.